Literature DB >> 26477980

Radiation therapy and grade II/III oligodendroglial tumors.

Caroline Chung1,2, Normand Laperriere1,2.   

Abstract

Radiotherapy has been a longstanding treatment option for low-grade glioma. Improvements in tumor control and radiation-related toxicity may be attributed to advances in neuroimaging as well as radiotherapy planning and delivery. The discovery of various molecular prognostic factors have aided in patient selection for radiotherapy. These prognostic and predictive factors may also play a key role in determining which patients are likely to benefit most from combined systemic therapy and radiation.

Entities:  

Keywords:  IMRT; OARs; astrocytoma; chemotherapy; intensity modulated radiotherapy; low-grade glioma; oligodendroglioma; organs at risk; quality of life; radiation necrosis; radiotherapy; temozolomide

Mesh：

Year:  2015        PMID： 26477980      PMCID： PMC6082334          DOI： 10.2217/cns.15.25

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


  24 in total

1.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.

Authors: 
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

2.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study.

Authors:  E Shaw; R Arusell; B Scheithauer; J O'Fallon; B O'Neill; R Dinapoli; D Nelson; J Earle; C Jones; T Cascino; D Nichols; R Ivnik; R Hellman; W Curran; R Abrams
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

3.  Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.

Authors:  M D Prados; C Scott; W J Curran; D F Nelson; S Leibel; S Kramer
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

Review 4.  Management of low-grade glioma.

Authors:  Nader Pouratian; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

5.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

6.  Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma. A phase II study.

Authors:  B Jeremic; Y Shibamoto; D Grujicic; B Milicic; M Stojanovic; N Nikolic; A Dagovic
Journal:  Radiother Oncol       Date:  1998-10       Impact factor: 6.280

Review 7.  Chemotherapy in low-grade gliomas.

Authors:  Aurélien Viaccoz; Alain Lekoubou; François Ducray
Journal:  Curr Opin Oncol       Date:  2012-11       Impact factor: 3.645

8.  Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

Authors:  M J van den Bent; M J B Taphoorn; A A Brandes; J Menten; R Stupp; M Frenay; O Chinot; J M Kros; C C D van der Rijt; Ch J Vecht; A Allgeier; T Gorlia
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

9.  Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.

Authors:  Jan C Buckner; Dean Gesme; Judith R O'Fallon; Julie E Hammack; Scott Stafford; Paul D Brown; Roland Hawkins; Bernd W Scheithauer; Bradley J Erickson; Ralph Levitt; Edward G Shaw; Robert Jenkins
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

10.  Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

Authors:  Edward G Shaw; Meihua Wang; Stephen W Coons; David G Brachman; Jan C Buckner; Keith J Stelzer; Geoffrey R Barger; Paul D Brown; Mark R Gilbert; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  1 in total

1.  Cognitive and brain structural changes in long-term oligodendroglial tumor survivors.

Authors:  Nuria Cayuela; Esteban Jaramillo-Jiménez; Estela Càmara; Carles Majós; Noemi Vidal; Anna Lucas; Miguel Gil-Gil; Francesc Graus; Jordi Bruna; Marta Simó
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.